Viokase 16, Viokase16 Plus Nexium and Nexium Alone
Information source: University of Florida
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Chronic Pancreatitis
Intervention: Nexium (esomeprazole magnesium) (Drug); Placebo to Nexium (Drug); Viokase 16 (pancrelipase) + Nexium (Drug); Viokase 16 + placebo to Nexium (Drug)
Phase: Phase 1
Sponsored by: University of Florida
Official(s) and/or principal investigator(s):
Phillip P Toskes, M.D., Principal Investigator, Affiliation: University of Florida
Our primary hypothesis is that the addition of Nexium to Viokase 16 will decrease the
chronic abdominal pain in patients with small duct chronic pancreatitis in a superior
fashion compared to Viokase 16 plus placebo or to Nexium alone. A secondary hypothesis would
be an increase in quality of life. Our objective is to elucidate the role of Nexium in the
control of pancreatic pain, quality of life, and narcotic usage alone or when added to
Viokase 16. Our endpoints are the reduction of abdominal pain, decreased pain medication
usage, decreased ER visits and decreased hospital admissions for abdominal pain.
Official title: A Randomized, Single Site, Double Blind, Fixed Dose, Cross Over Study of Viokase 16, Viokase16 Plus Nexium and Nexium Alone in the Reduction of Abdominal Pain in Patients With Chronic Pancreatitis
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Reduction of Abdominal Pain for Participants Taking Nexium Alone.
Reduction of Abdominal Pain for Participants Taking Placebo to Nexium
Reduction of Abdominal Pain in Participants Taking Viokase 16 Plus Nexium
Reduction of Abdominal Pain in Participants Taking Viokase 16 Plus Placebo.
Minimum age: 18 Years.
Maximum age: 75 Years.
1. Males and females age 18 to 75 years inclusive. Female subjects of child bearing
potential or less than two years post-menopausal must use a medically acceptable form
of birth control or barrier method and have a negative pregnancy test prior to entry
2. History of abdominal pain associated with chronic pancreatitis
3. Evidence of chronic pancreatitis as manifested by an abnormal secretin test,
calcification of the pancreas on plain film, an abnormal CT showing a dilated
pancreatic duct and/or atrophy, an abnormal
Endoscopicretrogradecholangeopancreatography (ERCP), or diffuse changes on Endoscopic
Ultrasound (EUS), fecal elastase > 100ug/g stool, or serum trypsinogen > 20ng/ml
1. Subjects on enzyme therapy within the last 14 days, proton pump inhibitor (PPI)within
the last 7 days, or octreotide within 48 hours.
2. Subjects with known hypersensitivity to pork or exogenous or pancreatic enzymes.
3. Female subjects who are pregnant or lactating
4. Subject use of enzyme therapy other than that called for in this study
5. Subject use of therapeutic amounts of antacids or H2 receptor antagonists during the
course of the study.
6. Past history of documented steatorrhea by 72 hour fecal fat determination or current
history consistent with steatorrhea -
Locations and Contacts
University of Florida, Gainesville, Florida 32610, United States
Starting date: February 2009
Last updated: February 20, 2013